Progranulin
Also known as: Acrogranin, GEP, Granulin-epithelin precursor, GRN protein, PC-cell-derived growth factor, PGRN
Source Progranulin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Progranulin (PGRN) is a secreted glycoprotein growth factor that functions as an adipokine and a neurotrophic factor. It influences whole‑body metabolism, inflammation, and neuronal survival. Research focuses on its protective role in atherosclerosis and its potential as a disease‑modifying therapy for neurodegenerative disorders, especially frontotemporal dementia caused by GRN loss‑of‑function mutations.
Mechanism of Action
Progranulin regulates lysosomal biogenesis and modulates microglial activity through pathways that include Trem2 and Cx3cr1, acting as an immune checkpoint that dampens neuroinflammation. In peripheral tissues it acts as an adipokine, influencing lipid handling and inflammatory signaling that can affect atherosclerotic processes. The combined actions support neuronal health and vascular homeostasis.
What the Research Shows
A 2022 review classified progranulin among protective adipokines that may mitigate atherosclerosis. Multiple reviews (2022, 2018, 2019, 2024) describe how GRN loss‑of‑function mutations lead to frontotemporal dementia and increase risk for Alzheimer’s, Parkinson’s, ALS and related disorders. Elevating progranulin levels is proposed as a therapeutic strategy, with pre‑clinical models showing restored lysosomal function and reduced microglial inflammation. Ongoing clinical trials are testing recombinant or gene‑based approaches, but no disease‑modifying product has yet received regulatory approval. Biomarker studies measure CSF or blood progranulin to track target engagement.
Reported Benefits
Evidence suggests that increasing progranulin could modify disease course in GRN‑linked frontotemporal dementia by restoring lysosomal function and limiting neuroinflammation. Its adipokine activity may also confer vascular protection, potentially slowing atherosclerotic plaque development. Early-phase studies aim to demonstrate these neuroprotective and cardiometabolic benefits.
Limitations of the Evidence
Most data are pre‑clinical or derived from observational studies; robust human efficacy data are lacking. Clinical trials are still early‑phase, and no FDA‑approved indication exists. The heterogeneity of neurodegenerative diseases means benefits may be limited to specific genetic sub‑populations. Long‑term safety and optimal dosing remain undefined.
Safety Considerations
The abstracts do not report specific adverse events for progranulin. As an investigational protein therapy, potential risks include immunogenic reactions, injection‑site reactions, and procedure‑related complications for intrathecal delivery. Until trial results are published, safety cannot be fully characterized, and use should be confined to controlled research settings.
How It Is Administered
Progranulin is being explored as a recombinant protein administered by intrathecal, intravenous, or subcutaneous injection. Formulations are designed for systemic or central nervous system delivery, depending on the therapeutic target.
Routes of Administration
Goals & Uses
- Neuroprotection in Alzheimer's diseaseNeurologyLow
- Treatment of neuronal ceroid lipofuscinosis (NCL/Batten disease)Lysosomal Storage DisorderModerate
- Wound healing promotionTissue RepairLow
- Anti-inflammatory therapy (rheumatoid arthritis)InflammationLow
- Treatment of GRN-related frontotemporal dementiaNeurodegenerationModerate
Contraindications
- Active malignancyOncologyModerateUse caution or avoid depending on agent and context
- Known hypersensitivity to progranulin or recombinant formulation excipientsAllergy / ImmunologyHigh
Adverse Effects
- Immunogenicity / anti-drug antibody formationImmunologicalUnknown
- Potential oncogenic riskOncologyUnknown
- Infusion-related reactionsHypersensitivityUnknown
Drug Interactions
- TNF inhibitors (e.g., etanercept, adalimumab)Moderate
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- Pediatric patientsAgeRelative
- Patients with active or prior malignancyOncologicRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalNo approved formulation. Research and early clinical trials ongoing for FTD and NCL indications.
- United StatesInvestigationalNo approved progranulin therapeutic. Related approaches (e.g., latozinemab/AL001 targeting sortilin to raise PGRN) have received FDA Breakthrough Therapy Designation for GRN-FTD. Gene therapy PR006 (AAV9-GRN) in Phase 1/2.
- United KingdomInvestigationalNo approved formulation. Subject to MHRA oversight for any clinical trial use.
No approved therapeutic formulation of progranulin exists in the US, EU, or UK as of 2024. Gene therapy and recombinant protein approaches targeting progranulin pathways are in early-phase clinical trials (e.g., for GRN-related FTD). Alector's AL001 (latozinemab) targets progranulin indirectly via sortilin inhibition and has received FDA Breakthrough Therapy Designation.
Evidence & Sources
- Journal ArticleModerateLiu L, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateRhinn H, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateGreaves CV, Rohrer JD2019-01-01T00:00:00.000000Z
- Journal ArticleModerateBuccellato FR, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateClark DG2024-01-01T00:00:00.000000Z
- Journal ArticleModerateHickman S, et al.2018-01-01T00:00:00.000000Z
Frequently Asked Questions
What diseases is progranulin being investigated for?
Research focuses on frontotemporal dementia caused by GRN mutations and other neurodegenerative disorders (Alzheimer’s, Parkinson’s, ALS), as well as its potential protective role in atherosclerosis.
How does progranulin influence brain health?
It supports lysosomal biogenesis, reduces microglial inflammation through Trem2/Cx3cr1 pathways, and promotes neuronal survival, thereby addressing key mechanisms of neurodegeneration.
Is progranulin an approved medication?
No. Progranulin is currently investigational; it is being tested in early‑phase clinical trials but has not received regulatory approval for any indication.
What routes of administration are being studied?
The protein is being delivered by intrathecal injection (directly into cerebrospinal fluid), intravenous infusion, or subcutaneous injection, depending on the trial design.
Are there known safety concerns?
Published abstracts do not detail adverse effects. Potential risks include immune reactions and procedure‑related complications, and safety data are still being gathered in clinical studies.
What is Progranulin?
Progranulin (PGRN) is a secreted glycoprotein growth factor that functions as an adipokine and a neurotrophic factor. It influences whole‑body metabolism, inflammation, and neuronal survival. Research focuses on its protective role in atherosclerosis and its potential as a disease‑modifying therapy for neurodegenerative disorders, especially frontotemporal dementia caused by GRN loss‑of‑function mutations.
What is Progranulin used for?
Progranulin is educationally associated with: Neuroprotection in Alzheimer's disease, Treatment of neuronal ceroid lipofuscinosis (NCL/Batten disease), Wound healing promotion, Anti-inflammatory therapy (rheumatoid arthritis), Treatment of GRN-related frontotemporal dementia. Educational only — not medical advice.
How is Progranulin administered?
Recorded routes of administration: Intrathecal, Intravenous, Subcutaneous.
What are the potential side effects of Progranulin?
Reported adverse effects include: Immunogenicity / anti-drug antibody formation, Potential oncogenic risk, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Progranulin?
Recorded contraindications: Active malignancy, Known hypersensitivity to progranulin or recombinant formulation excipients. Consult a qualified clinician before use.